Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Role of Gastric Acid Suppression Therapy in Erosive Esophagitis: From H2 Receptor Antagonists, Proton Pump Inhibitors, to Potassium-Competitive Acid Blockers

ACTA MEDICA INDONESIANA · Vol. 57 No. 2 (2025)

ISSN
2338-2732, 0125-9326
Terbit
2025-07-08
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng
Lisensi
creativecommons.org/licenses/by/4.0

Abstrak

Erosive esophagitis (EE) is an inflammation of the esophageal mucosa resulting from gastric and duodenal acid reflux, affecting approximately 55% of gastroesophageal reflux disease (GERD) patients in Indonesia. Effective acid suppression is essential for mucosal healing and symptomatic relief. Histamine-2 receptor antagonist (H2RA) was initially used for standard treatment for GERD, including EE, reducing gastric acid secretion by blocking H2 receptors. However, their efficacy is limited by inadequate acid suppression. Proton pump inhibitors (PPIs) became the mainstay therapy due to their stronger and longer-lasting acid suppression. Although PPIs have been proven to be quite effective, they have several limitations, including slow onset and inability to provide sustained acid suppression over a full 24-hour period. In recent years, Potassium-competitive acid blockers (PCAB) have become known as a category of drugs that effectively suppress gastric acid production, through a slightly different mechanism, and have advantages over PPIs, including faster onset and longer time of action. Both PPIs and PCABs can be used as therapy for patients with EE. PCABs are more recommended, especially in patients with severe grades of EE. H2RAs may still be considered in patients who have already received PPI therapy but continue to experience unresolved nocturnal acid symptoms.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 253 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Indonesia
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Hamzah ShatriAfiliasi tidak diketahui13
Dadang MakmunAfiliasi tidak diketahui9
Cleopas Martin RumendeAfiliasi tidak diketahui8
Murdani AbdullahAfiliasi tidak diketahui8
Siti SetiatiAfiliasi tidak diketahui7
Hasan MaulahelaAfiliasi tidak diketahui5
Robert SintoAfiliasi tidak diketahui4
Rudi PutrantoAfiliasi tidak diketahui4
Irsan HasanAfiliasi tidak diketahui4
Marcellus SimadibrataAfiliasi tidak diketahui4
Saskia Aziza NursyirwanAfiliasi tidak diketahui4
Rudy HidayatAfiliasi tidak diketahui4
Alvina WidhaniAfiliasi tidak diketahui3
Andhika RachmanAfiliasi tidak diketahui3
Kaka RenaldiAfiliasi tidak diketahui3
Erni Juwita NelwanAfiliasi tidak diketahui3
Nikko DarnindroAfiliasi tidak diketahui2
Ari F SyamAfiliasi tidak diketahui2
Lugyanti SukrismanAfiliasi tidak diketahui2
Muhadi MuhadiAfiliasi tidak diketahui2
Adityo SusiloAfiliasi tidak diketahui2
Juferdy KurniawanAfiliasi tidak diketahui2
Amanda Pitarini UtariAfiliasi tidak diketahui2
Pringgodigdo NugrohoAfiliasi tidak diketahui2
Siti Chandra WidjanantieAfiliasi tidak diketahui2
Cleopas M RumendeAfiliasi tidak diketahui2
Rabbinu Rangga PribadiAfiliasi tidak diketahui2
Andi YasmonAfiliasi tidak diketahui2
Ardi FindyartiniAfiliasi tidak diketahui2
Cosphiadi IrawanAfiliasi tidak diketahui2
Jessica MarsigitAfiliasi tidak diketahui2
Rahmi IstantiAfiliasi tidak diketahui2
Virly Nanda MuzellinaAfiliasi tidak diketahui2
Em YunirUniversity of Indonesia2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Role of Gastric Acid Suppression Therapy in Erosive Esophagitis: From H2 Receptor Antagonists, Proton Pump Inhibitors, to Potassium-Competitive Acid Blockers</dc:title>
	<dc:creator>Herardi, Ryan</dc:creator>
	<dc:creator>Syam, Ari Fahrial</dc:creator>
	<dc:creator>Fauzi, Achmad</dc:creator>
	<dc:creator>Rinaldi, Ikhwan </dc:creator>
	<dc:creator>Sandra, Sharon</dc:creator>
	<dc:creator>Arvant, Anisya Zakiyyahaya</dc:creator>
	<dc:subject xml:lang="en-US">Proton pump inhibitor</dc:subject>
	<dc:subject xml:lang="en-US">Histamine-2 receptor antagonist </dc:subject>
	<dc:subject xml:lang="en-US">Potassium-competitive acid blockers </dc:subject>
	<dc:subject xml:lang="en-US">erosive esophagitis</dc:subject>
	<dc:subject xml:lang="en-US">gastroesophageal reflux disease</dc:subject>
	<dc:subject xml:lang="en-US">Internal Medicine</dc:subject>
	<dc:subject xml:lang="en-US">gastroenterology</dc:subject>
	<dc:description xml:lang="en-US">Erosive esophagitis (EE) is an inflammation of the esophageal mucosa resulting from gastric and duodenal acid reflux, affecting approximately 55% of gastroesophageal reflux disease (GERD) patients in Indonesia. Effective acid suppression is essential for mucosal healing and symptomatic relief. Histamine-2 receptor antagonist (H2RA) was initially used for standard treatment for GERD, including EE, reducing gastric acid secretion by blocking H2 receptors. However, their efficacy is limited by inadequate acid suppression. Proton pump inhibitors (PPIs) became the mainstay therapy due to their stronger and longer-lasting acid suppression. Although PPIs have been proven to be quite effective, they have several limitations, including slow onset and inability to provide sustained acid suppression over a full 24-hour period. In recent years, Potassium-competitive acid blockers (PCAB) have become known as a category of drugs that effectively suppress gastric acid production, through a slightly different mechanism, and have advantages over PPIs, including faster onset and longer time of action. Both PPIs and PCABs can be used as therapy for patients with EE. PCABs are more recommended, especially in patients with severe grades of EE. H2RAs may still be considered in patients who have already received PPI therapy but continue to experience unresolved nocturnal acid symptoms.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2025-07-08</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/3034</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 57 No. 2 (2025): Acta Medica Indonesiana; 284</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/3034/805</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2025 Ryan Herardi, Ari Fahrial Syam, Achmad Fauzi, Ikhwan  Rinaldi, Sharon Sandra, Anisya Zakiyyahaya Arvant</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by/4.0</dc:rights>
</oai_dc:dc>